Phase I pilot study of INT 0036 as a potential therapy for schizophrenia.

Next Previous
Trial Profile

Phase I pilot study of INT 0036 as a potential therapy for schizophrenia.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs INT 0036 (Primary) ; INT 0036
  • Indications Schizophrenia
  • Focus First in man; Pharmacokinetics

    • Most Recent Events

    • 10 Nov 2014 New trial record
    • 03 Nov 2014 Results published in an IntelGenx Corp. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top